Skip to content
MarketScale
‹ Back to IndustriesHealthcare

Healthcare integration forecasted to grow 10 percent by Market Research Engine

Over the past decade, the healthcare industry has been in a continual process of consolidation and transformation, greatly affecting healthcare integration. Massive changes are occurring within each sector and between sectors, as well. Insurers continue to grow, hospitals are acquiring other hospitals and physician practices, and medical providers are opening or joining value-based relationships while…

This story was produced through MarketScale. See how Healthcare teams put it to work with Executive Thought Leadership.

Share

Get featured

Want to get featured in MarketScale Healthcare?

Create a free MarketScale workspace and get your company's expertise featured across our Healthcare coverage. No credit card, no demo required.

Start free

Over the past decade, the healthcare industry has been in a continual process of consolidation and transformation, greatly affecting healthcare integration. Massive changes are occurring within each sector and between sectors, as well. Insurers continue to grow, hospitals are acquiring other hospitals and physician practices, and medical providers are opening or joining value-based relationships while taking efforts to keep one foot in the fee-for-service world. Health IT vendors are consolidating as well.

The key to remaining nimble and responsive in this changing landscape is greater alignment and integration, which is growing faster than other healthcare market segments

According to a report by Market Research Engine, the global healthcare IT integration market is expected to grow at a compound annual growth rate (CAGR) of 10.2% over the next few years and exceed more than $3.73 billion by 2022. In addition, a McKinsey forecast estimates vertical integration represented as much as 50% of all healthcare activity in 2016 and 2017 and expects that trend to continue. McKinsey believes data, analytics, and information services will be the sector with the fastest growth rate at 16% to 18% over the next five years.

Hospitals can save millions through partnerships

A significant driver of consolidation in the healthcare industry is cost reduction. A small clinic or hospital, for example, can save millions on a new EHRElectronic Health Record (EHR), as defined in Defining Key Health Information Technology Terms (The National Alliance for Health Information Technology, April 28, 2008): An electronic record of health-related information on an individual that conform… More system by partnering with a larger healthcare system or provider. Consolidation also enables consistency across all areas of information and data management. Unfortunately, due to the siloed and dispersed nature of integrated hospital IT applications, and the countless sources of patient data at each facility, most EHRs were not designed to share data or to be interoperable with other systems.

IT integration is the key to leveraging the power of EHR systems

While much attention has been placed on the EHR system itself, sustainable health IT systems depend on an interoperable health data layer that allows the exchange of data between applications. This integration layer serves as the catalyst for all health data activities and allows IT departments to gain full control of their patients’ health data.

When a healthcare organization establishes a strategic data framework, the organization can easily parse, integrate, and exchange data between applications, systems, and locations, and updates can be rolled out seamlessly. It also allows an organization to be more responsive and nimble so it can quickly respond to market changes and implement changes at the clinical application layer and make technology choices that complement and improve workflows.

Download our white paper: Strategic data framework: Healthcare searches for IT stability to manage and implement change

Now is the time to address integration

In the wake of so many changes in healthcare IT, health integration services are only expected to grow, so now is the time to have the right interoperability foundation in place. Corepoint Health has the experience and strength to deliver a dramatically simplified approach to internal and external data integration and health information exchange for hospitals, radiology centers, laboratories, and clinics. Our innovative software will streamline your IT environment, provide a fast track to achieving your interoperability goals, and create operational leverage within your organization.

Your experts belong here

Every story in MarketScale Healthcare starts with a company putting its clinicians, service-line leaders, and field engineers on the record. Buyers are already reading this topic. The only question is whose experts they find.

Service-line buyers vet vendors quietly, and your clinicians become the proof they find while doing it.

Get your team featuredSee how it works15 minutes, straight to a calendar.
B2B Weekly

The week in Healthcare, and sixteen other industries, every Monday.

Ten stories, one-line takes, five minutes. Free.

Healthcare: are you visible to AI?

Before they reach out, Healthcare buyers ask AI engines which vendors to trust. Explore how your experts, customers, and partners can become useful content for buyers and AI search.

Free plan

You just read one Healthcare expert. Your company is full of them.

This article was produced through MarketScale. The same platform turns your clinicians, service-line leaders, and field engineers into the articles, video, and social content Healthcare buyers are searching for. Create a free workspace and see it with your own people. No credit card, no demo required.

NPS +73 · 1,000+ creators · 38+ countries

What you get, free

Your own MarketScale workspace, up to 10 people
One professional video edit a month for qualifying companies
Media requests to your crowd, remote recording, AI writing tools
$0, no credit card, nothing that expires

More Healthcare Insights

NICE recommends Enhertu for HER2-low advanced breast cancer in England

NICE recommends Enhertu for HER2-low advanced breast cancer in England

American Pharmaceutical Review reported that NICE has recommended AstraZeneca and Daiichi Sankyo’s Enhertu for routine NHS use in people with HER2-low advanced breast cancer, following a commercial agreement and updates to NICE’s methods under the U.K.-U.S. Pharmaceutical Pricing Agreement.

  • 01NICE tied the reversal to 2026 changes: higher cost-effectiveness thresholds that took effect in April and a new quality-of-life assessment method published Aug. 27, 2026.
  • 02Access planning still varies by nation: Fierce Pharma reported Wales requires funding within 60 days of final guidance, while Scotland and Northern Ireland follow separate processes.

Sep 21, 2026

Eli Lilly’s $6.5B Houston Bet Highlights U.S. Pharma Reshoring

Eli Lilly’s $6.5B Houston Bet Highlights U.S. Pharma Reshoring

Eli Lilly is investing $6.5 billion in a Houston manufacturing facility set to open around 2030, primarily to scale production of Foundayo, its oral GLP-1 treatment. The project signals a broader shift in U.S. pharmaceutical manufacturing reshoring and underscores the supply chain challenge of forecasting demand and building capacity years in advance for breakthrough therapeutics.

  • 01Eli Lilly commits $6.5 billion to a Houston pharmaceutical manufacturing facility due for completion around 2030, one of the largest single U.S. pharma production investments in recent years
  • 02GLP-1 demand forecasting remains highly uncertain: Lilly's CEO noted that one-third of new GLP-1 pill patients are now choosing Foundayo, illustrating fast-moving market share shifts that complicate production planning years in advance
  • 03Houston's selection reflects industrial capacity and workforce depth, positioning the region as a biomanufacturing corridor and creating long-term hiring demand in engineering, quality control, and skilled trades

Sep 21, 2026

Waiting for perfectly clean data is stalling healthcare AI, not protecting it

Healthcare organizations often delay AI initiatives waiting for perfectly clean data, but this assumption no longer holds: reliable subsets and synthetic data allow projects to start now while data work continues in parallel. Success requires starting with business outcomes rather than technology capabilities, and embedding governance in product strategy before implementation, not after.

  • 01Waiting for 100% clean data is effectively a decision never to start; hospital AI projects can begin on reliable data subsets while quality work continues in parallel.
  • 02Frame AI decisions around business outcomes (revenue growth, cost reduction, competitive advantage, new products, or ecosystem influence) rather than asking what AI can do.
  • 03Governance should be part of product strategy before design or purchase, especially as agentic AI takes actions—such as handling many revenue-cycle denials—while routing the rest to humans.

Sep 21, 2026

Explore More Healthcare Insights

Read more expert perspectives from across Healthcare.

Browse Healthcare Hub

For B2B teams

Your experts could be publishing here

Stories like this one run on content MarketScale captures from real practitioners. See how your team's expertise becomes coverage in Healthcare and beyond.

Book a 15-minute demo

Or call us. No forms required. We pick up. 214-945-2512